Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 24 studies | 33% ± 10% | |
pericyte | 14 studies | 25% ± 6% | |
capillary endothelial cell | 11 studies | 32% ± 9% | |
endothelial cell of artery | 10 studies | 39% ± 15% | |
vein endothelial cell | 10 studies | 31% ± 12% | |
endothelial cell of vascular tree | 10 studies | 29% ± 8% | |
smooth muscle cell | 5 studies | 21% ± 6% | |
fibroblast | 4 studies | 20% ± 3% | |
glomerular endothelial cell | 3 studies | 20% ± 4% |
Insufficient scRNA-seq data for expression of LRRC32 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 12826.14 | 457 / 459 | 95% | 39.07 | 1065 / 1118 |
kidney | 100% | 9691.00 | 89 / 89 | 94% | 75.00 | 851 / 901 |
adrenal gland | 99% | 6648.97 | 256 / 258 | 93% | 39.34 | 215 / 230 |
lung | 100% | 20792.34 | 578 / 578 | 91% | 23.79 | 1052 / 1155 |
prostate | 96% | 5077.41 | 236 / 245 | 93% | 21.29 | 465 / 502 |
intestine | 93% | 4380.86 | 896 / 966 | 94% | 31.87 | 496 / 527 |
thymus | 100% | 8780.58 | 650 / 653 | 87% | 24.33 | 528 / 605 |
stomach | 84% | 3243.60 | 302 / 359 | 95% | 37.82 | 273 / 286 |
bladder | 100% | 7436.29 | 21 / 21 | 78% | 21.64 | 393 / 504 |
esophagus | 77% | 3948.90 | 1119 / 1445 | 87% | 22.07 | 159 / 183 |
skin | 79% | 4126.56 | 1438 / 1809 | 79% | 20.62 | 374 / 472 |
uterus | 99% | 7161.47 | 169 / 170 | 59% | 13.60 | 269 / 459 |
ovary | 55% | 2139.68 | 99 / 180 | 86% | 30.66 | 369 / 430 |
pancreas | 32% | 725.63 | 106 / 328 | 98% | 82.35 | 175 / 178 |
adipose | 100% | 18911.76 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 13076.07 | 1333 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 6014.98 | 239 / 241 | 0% | 0 | 0 / 0 |
heart | 99% | 5613.07 | 849 / 861 | 0% | 0 | 0 / 0 |
liver | 21% | 581.08 | 48 / 226 | 74% | 17.53 | 301 / 406 |
lymph node | 0% | 0 | 0 / 0 | 79% | 27.75 | 23 / 29 |
brain | 34% | 946.63 | 892 / 2642 | 45% | 7.70 | 314 / 705 |
muscle | 75% | 2400.09 | 601 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 60% | 8.38 | 27 / 45 |
eye | 0% | 0 | 0 / 0 | 44% | 5.48 | 35 / 80 |
peripheral blood | 1% | 19.01 | 8 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035592 | Biological process | establishment of protein localization to extracellular region |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0062009 | Biological process | secondary palate development |
GO_0046007 | Biological process | negative regulation of activated T cell proliferation |
GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
GO_0001818 | Biological process | negative regulation of cytokine production |
GO_0005615 | Cellular component | extracellular space |
GO_0009986 | Cellular component | cell surface |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005886 | Cellular component | plasma membrane |
GO_0031012 | Cellular component | extracellular matrix |
GO_0050431 | Molecular function | transforming growth factor beta binding |
GO_0141069 | Molecular function | receptor ligand inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | LRRC32 |
Protein name | Leucine rich repeat containing 32 Transforming growth factor beta activator LRRC32 (Garpin) (Glycoprotein A repetitions predominant) (GARP) (Leucine-rich repeat-containing protein 32) |
Synonyms | D11S833E |
Description | FUNCTION: Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space . Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta . Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta . Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs) . Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity). . |
Accessions | ENST00000404995.5 ENST00000407242.6 ENST00000260061.9 ENST00000421973.1 Q14392 C9JYU3 |